Skip to main content
Erschienen in: Japanese Journal of Radiology 8/2021

20.03.2021 | Original Article

Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer

verfasst von: Erina Kato, Naoko Mori, Shunji Mugikura, Satoko Sato, Takanori Ishida, Kei Takase

Erschienen in: Japanese Journal of Radiology | Ausgabe 8/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the diagnostic performance of ultrafast and standard dynamic contrast-enhanced (DCE)-MRI in evaluating the residual disease after neoadjuvant chemotherapy (NAC) for breast cancer.

Materials and methods

Sixty-seven consecutive patients underwent MRI after NAC. Visual analysis of enhancement was performed on ultrafast and standard DCE-MRI, and compared between no residual disease and residual disease groups. The lesion diameters measured on the last phase of ultrafast DCE-MRI and early and delayed phases of standard DCE-MRI were compared with pathological diameter of entire residual cancer and residual invasive ductal carcinoma (IDC).

Results

The visual analysis in the delayed phase of standard DCE-MRI exhibited the highest sensitivity (90%), whereas ultrafast DCE-MRI revealed the highest positive predictive value (92%). There were no significant differences between the diameters in the delayed phase of the standard DCE-MRI and the pathological entire residual cancer (p = 0.97), and the diameters in ultrafast DCE-MRI and the pathological residual IDC (p = 0.97).

Conclusion

The delayed phase of standard DCE-MRI may be effective for detecting the residual disease and evaluating the extension of entire residual cancer. Enhancement in ultrafast DCE-MRI may be strongly suggestive of the presence of residual disease, and effective for evaluating the extension of residual IDC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335–43.CrossRef King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol. 2015;12:335–43.CrossRef
2.
Zurück zum Zitat Kobayashi K, Horii R, Ito Y, Miyagi Y, Ohno S, Iwase T, et al. Prognostic significance of histological therapeutic effect in preoperative chemotherapy for breast cancer: prognostic analysis in breast cancer. Pathol Int. 2016;66:8–14.CrossRef Kobayashi K, Horii R, Ito Y, Miyagi Y, Ohno S, Iwase T, et al. Prognostic significance of histological therapeutic effect in preoperative chemotherapy for breast cancer: prognostic analysis in breast cancer. Pathol Int. 2016;66:8–14.CrossRef
3.
Zurück zum Zitat Chaturvedi S, McLaren C, Schofield AC, Ogston KN, Sarkar TK, Hutcheon AW, et al. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast? Breast Cancer Res Treat. 2005;93:151–8.CrossRef Chaturvedi S, McLaren C, Schofield AC, Ogston KN, Sarkar TK, Hutcheon AW, et al. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast? Breast Cancer Res Treat. 2005;93:151–8.CrossRef
4.
Zurück zum Zitat Mukai H, Arihiro K, Shimizu C, Masuda N, Miyagi Y, Yamaguchi T, et al. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society. Breast Cancer. 2016;23:73–7.CrossRef Mukai H, Arihiro K, Shimizu C, Masuda N, Miyagi Y, Yamaguchi T, et al. Stratifying the outcome after neoadjuvant treatment using pathological response classification by the Japanese Breast Cancer Society. Breast Cancer. 2016;23:73–7.CrossRef
5.
Zurück zum Zitat von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–28.CrossRef von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617–28.CrossRef
6.
Zurück zum Zitat Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.CrossRef Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376(22):2147–59.CrossRef
7.
Zurück zum Zitat Park CC, Schnitt SJ. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18:1668–75.CrossRef Park CC, Schnitt SJ. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18:1668–75.CrossRef
9.
Zurück zum Zitat von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRef von Minckwitz G, Untch M, Blohmer J-U, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796–804.CrossRef
10.
Zurück zum Zitat Lobbes MBI. Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction. Breast Cancer Res Treat. 2012;136:313–4.CrossRef Lobbes MBI. Treatment response evaluation by MRI in breast cancer patients receiving neoadjuvant chemotherapy: there is more than just pathologic complete response prediction. Breast Cancer Res Treat. 2012;136:313–4.CrossRef
11.
Zurück zum Zitat Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. JNCI J Natl Cancer Inst. 2013;105(5):321–33.CrossRef Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. JNCI J Natl Cancer Inst. 2013;105(5):321–33.CrossRef
12.
Zurück zum Zitat Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer. 2015;8(15):662.CrossRef Marinovich ML, Macaskill P, Irwig L, Sardanelli F, Mamounas E, von Minckwitz G, et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer. 2015;8(15):662.CrossRef
13.
Zurück zum Zitat De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119:1776–83.CrossRef De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer Research Consortium trial 017. Cancer. 2013;119:1776–83.CrossRef
14.
Zurück zum Zitat Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14(8):1371–9.CrossRef Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004;14(8):1371–9.CrossRef
15.
Zurück zum Zitat Rieber A, Brambs H-J, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002;12(7):1711–9.CrossRef Rieber A, Brambs H-J, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol. 2002;12(7):1711–9.CrossRef
16.
Zurück zum Zitat American College of Radiology. Breast imaging reporting and data system (BI-RADS). 5th ed. American College of Radiology: Reston; 2013. American College of Radiology. Breast imaging reporting and data system (BI-RADS). 5th ed. American College of Radiology: Reston; 2013.
17.
Zurück zum Zitat Kim H, Kim HH, Park JS, Shin HJ, Cha JH, Chae EY, et al. Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detection. Br J Radiol. 2014;87:20140142.CrossRef Kim H, Kim HH, Park JS, Shin HJ, Cha JH, Chae EY, et al. Prediction of pathological complete response of breast cancer patients undergoing neoadjuvant chemotherapy: usefulness of breast MRI computer-aided detection. Br J Radiol. 2014;87:20140142.CrossRef
18.
Zurück zum Zitat Choi BB, Kim SH. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Acta Radiol. 2015;56:790–7.CrossRef Choi BB, Kim SH. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy. Acta Radiol. 2015;56:790–7.CrossRef
19.
Zurück zum Zitat Rieber A, Zeitler H, Rosenthal H, Görich J, Kreienberg R, Brambs HJ, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol. 1997;70:452–8.CrossRef Rieber A, Zeitler H, Rosenthal H, Görich J, Kreienberg R, Brambs HJ, et al. MRI of breast cancer: influence of chemotherapy on sensitivity. Br J Radiol. 1997;70:452–8.CrossRef
20.
Zurück zum Zitat Kim S-Y, Cho N, Park I-A, Kwon BR, Shin SU, Kim SY, et al. Dynamic contrast-enhanced breast MRI for evaluating residual tumor size after neoadjuvant chemotherapy. Radiology. 2018;289:327–34.CrossRef Kim S-Y, Cho N, Park I-A, Kwon BR, Shin SU, Kim SY, et al. Dynamic contrast-enhanced breast MRI for evaluating residual tumor size after neoadjuvant chemotherapy. Radiology. 2018;289:327–34.CrossRef
21.
Zurück zum Zitat Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol. 2002;179(5):1193–9.CrossRef Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol. 2002;179(5):1193–9.CrossRef
22.
Zurück zum Zitat Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181(5):1275–82.CrossRef Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. Am J Roentgenol. 2003;181(5):1275–82.CrossRef
23.
Zurück zum Zitat Abe H, Mori N, Tsuchiya K, Schacht DV, Pineda FD, Jiang Y, et al. Kinetic analysis of benign and malignant breast lesions with ultrafast dynamic contrast-enhanced MRI: comparison with standard kinetic assessment. Am J Roentgenol. 2016;207(5):1159–66.CrossRef Abe H, Mori N, Tsuchiya K, Schacht DV, Pineda FD, Jiang Y, et al. Kinetic analysis of benign and malignant breast lesions with ultrafast dynamic contrast-enhanced MRI: comparison with standard kinetic assessment. Am J Roentgenol. 2016;207(5):1159–66.CrossRef
24.
Zurück zum Zitat Mori N, Pineda FD, Tsuchiya K, Mugikura S, Takahashi S, Karczmar GS, et al. Fast temporal resolution dynamic contrast-enhanced MRI: histogram analysis versus visual analysis for differentiating benign and malignant breast lesions. Am J Roentgenol. 2018;211(4):933–9.CrossRef Mori N, Pineda FD, Tsuchiya K, Mugikura S, Takahashi S, Karczmar GS, et al. Fast temporal resolution dynamic contrast-enhanced MRI: histogram analysis versus visual analysis for differentiating benign and malignant breast lesions. Am J Roentgenol. 2018;211(4):933–9.CrossRef
25.
Zurück zum Zitat Pineda FD, Medved M, Wang S, Fan X, Schacht DV, Sennett C, et al. Ultrafast bilateral DCE-MRI of the breast with conventional Fourier sampling. Acad Radiol. 2016;23(9):1137–44.CrossRef Pineda FD, Medved M, Wang S, Fan X, Schacht DV, Sennett C, et al. Ultrafast bilateral DCE-MRI of the breast with conventional Fourier sampling. Acad Radiol. 2016;23(9):1137–44.CrossRef
26.
Zurück zum Zitat Mori N, Sheth D, Abe H. Nonmass enhancement breast lesions: diagnostic performance of kinetic assessment on ultrafast and standard dynamic contrast-enhanced MRI in comparison with morphologic evaluation. Am J Roentgenol. 2020;215(2):511–8.CrossRef Mori N, Sheth D, Abe H. Nonmass enhancement breast lesions: diagnostic performance of kinetic assessment on ultrafast and standard dynamic contrast-enhanced MRI in comparison with morphologic evaluation. Am J Roentgenol. 2020;215(2):511–8.CrossRef
27.
Zurück zum Zitat Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Newstead GM. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: A sensitivity and specificity study. Magn Reson Med. 2008;59:747–54.CrossRef Jansen SA, Fan X, Karczmar GS, Abe H, Schmidt RA, Newstead GM. Differentiation between benign and malignant breast lesions detected by bilateral dynamic contrast-enhanced MRI: A sensitivity and specificity study. Magn Reson Med. 2008;59:747–54.CrossRef
28.
Zurück zum Zitat Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91–101.CrossRef Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging. 1997;7:91–101.CrossRef
29.
Zurück zum Zitat Mori N, Abe H, Mugikura S, Takasawa C, Sato S, Miyashita M, et al. Ultrafast dynamic contrast-enhanced breast mri: kinetic curve assessment using empirical mathematical model validated with histological microvessel density. Acad Radiol. 2019;26(7):e141–9.CrossRef Mori N, Abe H, Mugikura S, Takasawa C, Sato S, Miyashita M, et al. Ultrafast dynamic contrast-enhanced breast mri: kinetic curve assessment using empirical mathematical model validated with histological microvessel density. Acad Radiol. 2019;26(7):e141–9.CrossRef
30.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159.CrossRef Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159.CrossRef
31.
Zurück zum Zitat Kanazawa T, Akashi-Tanaka S, Iwamoto E, Takasugi M, Shien T, Kinoshita T, et al. Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J. 2005;11:311–6.CrossRef Kanazawa T, Akashi-Tanaka S, Iwamoto E, Takasugi M, Shien T, Kinoshita T, et al. Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic imaging in primary breast cancer patients. Breast J. 2005;11:311–6.CrossRef
32.
Zurück zum Zitat Leddy R, Irshad A, Metcalfe A, Mabalam P, Abid A, Ackerman S, et al. Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: is the accuracy affected by breast density or cancer subtype?: Accuracy of Tumor Size on MM, US, and MRI. J Clin Ultrasound. 2016;44:17–25.CrossRef Leddy R, Irshad A, Metcalfe A, Mabalam P, Abid A, Ackerman S, et al. Comparative accuracy of preoperative tumor size assessment on mammography, sonography, and MRI: is the accuracy affected by breast density or cancer subtype?: Accuracy of Tumor Size on MM, US, and MRI. J Clin Ultrasound. 2016;44:17–25.CrossRef
33.
Zurück zum Zitat Lehman CD, Hendrick RE, Maki DD, Schnall MD. MRI Evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356(13):1295–303.CrossRef Lehman CD, Hendrick RE, Maki DD, Schnall MD. MRI Evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356(13):1295–303.CrossRef
34.
Zurück zum Zitat Behjatnia B, Sim J, Bassett LW, Moatamed NA, Apple SK. Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. Int J Clin Exp Pathol. 2010;3(3):303–9.PubMedPubMedCentral Behjatnia B, Sim J, Bassett LW, Moatamed NA, Apple SK. Does size matter? Comparison study between MRI, gross, and microscopic tumor sizes in breast cancer in lumpectomy specimens. Int J Clin Exp Pathol. 2010;3(3):303–9.PubMedPubMedCentral
35.
Zurück zum Zitat Mennella S, Garlaschi A, Paparo F, Perillo M, Celenza M, Massa T, et al. Magnetic resonance imaging of breast cancer: factors affecting the accuracy of preoperative lesion sizing. Acta Radiol. 2015;56:260–8.CrossRef Mennella S, Garlaschi A, Paparo F, Perillo M, Celenza M, Massa T, et al. Magnetic resonance imaging of breast cancer: factors affecting the accuracy of preoperative lesion sizing. Acta Radiol. 2015;56:260–8.CrossRef
36.
Zurück zum Zitat Yeap BH, Muniandy S, Lee S-K, Sabaratnam S, Singh M. Specimen shrinkage and its influence on margin assessment in breast cancer. Asian J Surg. 2007;30:183–7.CrossRef Yeap BH, Muniandy S, Lee S-K, Sabaratnam S, Singh M. Specimen shrinkage and its influence on margin assessment in breast cancer. Asian J Surg. 2007;30:183–7.CrossRef
Metadaten
Titel
Value of ultrafast and standard dynamic contrast-enhanced magnetic resonance imaging in the evaluation of the presence and extension of residual disease after neoadjuvant chemotherapy in breast cancer
verfasst von
Erina Kato
Naoko Mori
Shunji Mugikura
Satoko Sato
Takanori Ishida
Kei Takase
Publikationsdatum
20.03.2021
Verlag
Springer Singapore
Erschienen in
Japanese Journal of Radiology / Ausgabe 8/2021
Print ISSN: 1867-1071
Elektronische ISSN: 1867-108X
DOI
https://doi.org/10.1007/s11604-021-01110-y

Weitere Artikel der Ausgabe 8/2021

Japanese Journal of Radiology 8/2021 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.